<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926185</url>
  </required_header>
  <id_info>
    <org_study_id>1118-KCS-100</org_study_id>
    <nct_id>NCT00926185</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of three different concentrations
      (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of
      dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84</measure>
    <time_frame>Day 84</time_frame>
    <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84</measure>
    <time_frame>Baseline (Day 0) and Day 84</time_frame>
    <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% Lifitegrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifitegrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0% Lifitegrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifitegrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0% Lifitegrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifitegrast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifitegrast</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>0.1% Lifitegrast</arm_group_label>
    <arm_group_label>1.0% Lifitegrast</arm_group_label>
    <arm_group_label>5.0% Lifitegrast</arm_group_label>
    <other_name>SAR 1118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form and HIPAA document

          -  Willing and able to comply with all study procedures

          -  Be at least 18 years of age

          -  Patient-reported history of dry eye in both eyes

          -  Demonstrate a positive response when exposed to the Controlled Adverse Environment
             model

          -  A negative urine pregnancy test if female of childbearing potential and must use
             adequate birth control throughout the study period

        Exclusion Criteria:

          -  Any ocular condition that, in the opinion of the Investigator, could affect study
             parameters including, but not limited to, active ocular infection, ocular
             inflammation, glaucoma, and/or diabetic retinopathy

          -  Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the
             study period

          -  Any blood donation or significant loss of blood within 56 days of Visit 1

          -  Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
             acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.

          -  Use of any topical ophthalmic preparations (including tear substitutes) 72 hrs prior
             to screening assessments and through the entire study period

          -  Any significant illness that could interfere with study parameters

          -  History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal
             refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical
             procedure within 12 months prior to Visit 1; or any scheduled ocular surgical
             procedure during the study period.

          -  Known history of alcohol and/or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ORA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Eye Care Group</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Eye Care</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ora, Inc. (two locations)</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mundorf Eye Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, P.A.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <results_first_submitted>August 9, 2016</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <disposition_first_submitted>July 2, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 9, 2013</disposition_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>ophthalmic delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lifitegrast</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was conducted in a Controlled Adverse Environment (CAE).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lifitegrast 0.1%</title>
        </group>
        <group group_id="P2">
          <title>Lifitegrast 1.0%</title>
        </group>
        <group group_id="P3">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Lifitegrast 0.1%</title>
        </group>
        <group group_id="B2">
          <title>Lifitegrast 1.0%</title>
        </group>
        <group group_id="B3">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="58"/>
            <count group_id="B5" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.14" spread="13.100"/>
                    <measurement group_id="B2" value="63.63" spread="11.883"/>
                    <measurement group_id="B3" value="62.26" spread="12.220"/>
                    <measurement group_id="B4" value="60.38" spread="12.930"/>
                    <measurement group_id="B5" value="62.34" spread="12.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84</title>
        <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
        <time_frame>Day 84</time_frame>
        <population>Intent-to-treat (ITT) population with LOCF defined as all randomized subjects. For the efficacy analysis, the Last Observation Carried Forward (LOCF) method will be used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Lifitegrast 0.1%</title>
          </group>
          <group group_id="O2">
            <title>Lifitegrast 1.0%</title>
          </group>
          <group group_id="O3">
            <title>Lifitegrast 5.0%</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84</title>
          <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
          <population>Intent-to-treat (ITT) population with LOCF defined as all randomized subjects. For the efficacy analysis, the Last Observation Carried Forward (LOCF) method will be used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.868"/>
                    <measurement group_id="O2" value="1.92" spread="0.768"/>
                    <measurement group_id="O3" value="1.83" spread="0.680"/>
                    <measurement group_id="O4" value="2.05" spread="0.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9381</p_value>
            <method>Dunnett’s test</method>
            <param_type>Treatment Effect</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Analysis of covariance model with treatment, baseline, and site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3585</p_value>
            <method>Dunnett’s test</method>
            <param_type>Treatment Effect</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Analysis of covariance model with treatment, baseline, and site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1375</p_value>
            <method>Dunnett’s test</method>
            <param_type>Treatment Effect</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Analysis of covariance model with treatment, baseline, and site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84</title>
        <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
        <time_frame>Baseline (Day 0) and Day 84</time_frame>
        <population>ITT set with LOCF was used for analysis of this outcome. Here, “n” signifies the number of participants evaluable for the respective time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Lifitegrast 0.1%</title>
          </group>
          <group group_id="O2">
            <title>Lifitegrast 1.0%</title>
          </group>
          <group group_id="O3">
            <title>Lifitegrast 5.0%</title>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84</title>
          <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
          <population>ITT set with LOCF was used for analysis of this outcome. Here, “n” signifies the number of participants evaluable for the respective time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-CAE: Baseline (n=57,56,58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.473"/>
                    <measurement group_id="O2" value="1.82" spread="0.508"/>
                    <measurement group_id="O3" value="1.77" spread="0.515"/>
                    <measurement group_id="O4" value="1.65" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-CAE: CFB to Day 84 (n=57,55,54,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.841"/>
                    <measurement group_id="O2" value="0.10" spread="0.735"/>
                    <measurement group_id="O3" value="0.05" spread="0.773"/>
                    <measurement group_id="O4" value="0.40" spread="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-CAE: Baseline (n=57,56,58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="0.417"/>
                    <measurement group_id="O2" value="3.28" spread="0.610"/>
                    <measurement group_id="O3" value="3.16" spread="0.523"/>
                    <measurement group_id="O4" value="3.04" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-CAE: CFB to Day 84 (n=57,55,54,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.962"/>
                    <measurement group_id="O2" value="2.88" spread="0.860"/>
                    <measurement group_id="O3" value="2.90" spread="0.918"/>
                    <measurement group_id="O4" value="2.62" spread="0.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until the end of follow-up visit, up to Day 86</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lifitegrast 0.1%</title>
        </group>
        <group group_id="E2">
          <title>Lifitegrast 1.0%</title>
        </group>
        <group group_id="E3">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Instillation site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="16" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

